A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis
Junnan Li, Pengchen Chen, Qiushuang Wu, Libin Guo, Ka Weng Leong, Kin Iong Chan, Hang Fai Kwok
Topics & Concepts
ErlotinibGefitinibLung cancerCancer researchEpidermal growth factor receptorErlotinib HydrochlorideMedicineFOXM1EGFR inhibitorsCell cycleTyrosine kinaseCancerPharmacologyOncologyInternal medicineReceptorFOXO transcription factor regulationCancer Mechanisms and TherapySignaling Pathways in Disease